Hepatic Encephalopathy Market to Hit USD 2.75 Billion by 2032

Posted 2026-02-12 06:24:07

“According to a new report published by Introspective Market Research, Hepatic Encephalopathy Market by Disease Type, Treatment Type, and End User, The Global Hepatic Encephalopathy Market Size Was Valued at USD 1.70 Billion in 2023 and is Projected to Reach USD 2.75 Billion by 2032, Growing at a CAGR of 5.50% from 2024 to 2032.”

Hepatic encephalopathy is a serious neuropsychiatric condition resulting from liver dysfunction, commonly associated with chronic liver diseases such as cirrhosis and acute liver failure. The condition arises due to the accumulation of toxins, particularly ammonia, which adversely affect brain function. Hepatic encephalopathy can range from minimal cognitive impairment to severe neurological symptoms, including confusion, altered consciousness, and coma.

The market for hepatic encephalopathy treatment is driven by increasing prevalence of liver diseases globally, rising alcohol consumption, growing cases of viral hepatitis, and an expanding geriatric population. Advances in pharmacological therapies, including ammonia-lowering agents and non-absorbable antibiotics, have significantly improved disease management and patient outcomes.

Additionally, increasing awareness among healthcare professionals, early diagnosis, and improved access to treatment options in both developed and emerging economies are supporting steady market growth. Ongoing research and development activities focused on novel therapies further contribute to the expansion of the hepatic encephalopathy market.

Market Segmentation

The Hepatic Encephalopathy Market is segmented into Disease Type, Treatment Type, and End User.
By Disease Type, the market is categorized into Type A, Type B, and Type C.
By Treatment Type, the market is categorized into Lactulose, Rifaximin, Antibiotics, and Other Therapies.
By End User, the market is categorized into Hospitals, Specialty Clinics, and Ambulatory Surgical Centers.

Growth Driver

The primary growth driver for the hepatic encephalopathy market is the rising global burden of chronic liver diseases, particularly cirrhosis and hepatitis-related complications. Increasing alcohol abuse, obesity-related non-alcoholic fatty liver disease (NAFLD), and viral hepatitis infections have led to a higher incidence of hepatic encephalopathy cases worldwide. As these conditions often require long-term medical management, demand for effective treatment solutions continues to rise. Improved diagnostic capabilities and greater physician awareness are also contributing to increased treatment rates, supporting sustained market growth.

Market Opportunity

A key market opportunity lies in the development of novel and targeted therapies aimed at improving patient compliance and reducing recurrence rates. Current treatment options, while effective, often involve long-term administration and may cause side effects. Pharmaceutical companies are increasingly investing in innovative drug formulations, combination therapies, and microbiome-based treatments. Furthermore, expanding healthcare infrastructure and improved access to advanced treatments in emerging markets present significant growth opportunities for market players during the forecast period.

Detailed Segmentation

Hepatic Encephalopathy Market, Segmentation

The Hepatic Encephalopathy Market is segmented on the basis of Disease Type, Treatment Type, and End User.

Disease Type

The Disease Type segment is further classified into Type A, Type B, and Type C. Among these, the Type C sub-segment accounted for the highest market share in 2023. Type C hepatic encephalopathy is primarily associated with liver cirrhosis, which represents the most common underlying cause of the condition globally. The high prevalence of cirrhosis, frequent disease recurrence, and need for continuous treatment contribute to the dominance of this segment. Increasing hospitalization rates and long-term disease management requirements further support its leading market position.

Treatment Type

The Treatment Type segment is further classified into Lactulose, Rifaximin, Antibiotics, and Other Therapies. Among these, the Lactulose sub-segment accounted for the highest market share in 2023. Lactulose remains the first-line therapy due to its proven efficacy in reducing ammonia levels, wide availability, and cost-effectiveness. Its long-standing clinical use and strong physician preference, especially in both acute and chronic management, continue to drive strong adoption across healthcare settings.

Some of The Leading/Active Market Players Are-

• AbbVie Inc. (U.S.)
• Salix Pharmaceuticals (U.S.)
• Mallinckrodt Pharmaceuticals (U.K.)
• Pfizer Inc. (U.S.)
• Bausch Health Companies Inc. (Canada)
• Takeda Pharmaceutical Company Limited (Japan)
• Lupin Limited (India)
• Sun Pharmaceutical Industries Ltd. (India)
• Dr. Reddy’s Laboratories Ltd. (India)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Aurobindo Pharma (India)
• Cipla Limited (India)
• Zydus Lifesciences Ltd. (India)
• Mylan N.V. (U.S.)
• Glenmark Pharmaceuticals (India)
and other active players.

Key Industry Developments

In March 2024, a leading pharmaceutical company expanded its hepatic encephalopathy drug portfolio by strengthening its manufacturing capacity to meet growing global demand.
This expansion aims to ensure uninterrupted supply, improve accessibility in emerging markets, and support long-term treatment needs, particularly in regions experiencing rising liver disease prevalence.

In September 2023, a major market player initiated a clinical study focused on next-generation therapies targeting ammonia reduction and gut microbiota modulation.
The study highlights the industry’s focus on innovative treatment approaches aimed at improving efficacy, reducing relapse rates, and enhancing patient quality of life.

Key Findings of the Study

• Type C disease segment dominated the market due to high cirrhosis prevalence
• Lactulose remains the leading treatment option globally
• North America held the largest market share
• Rising liver disease burden is a key growth driver
• Emerging markets offer strong future growth potential

More Info:- https://introspectivemarketresearch.com/reports/hepatic-encephalopathy-market/

About Us

At Introspective Market Research Private Limited, we are a forward-thinking research consulting firm committed to driving growth in the Hepatic Encephalopathy Market. With deep insights, strategic solutions, and holistic research, we empower businesses to achieve success and dominance in the global Hepatic Encephalopathy Market industry.